EBRCZ
What one share of EBR Systems holds
Surgical and Medical Instruments and Apparatus
Regulatory approvals/clearances. Our business strategy depends on the successful FDA submission of our PAS and ongoing annual reporting of our WiSE CRT System to the FDA.
EBR Systems’s numbers from its SEC filings, divided by its shares. Results cover the last 12 months to 2026-06-30; the balance sheet is as of 2026-06-30.
| Sales | $0.14 |
|---|---|
| Profit | −$1.32 |
| Capex (buildings and equipment) | $0.19 |
| Free cash flow | −$1.62 |
| Cash and investments | $1.15 |
| Debt | $0.56 |
| Book value | $0.91 |
Per share by fiscal year
| Year | Sales | Profit | Capex | Free cash | Dividends | Book value |
|---|---|---|---|---|---|---|
| 2023 | — | −$1.21 | $0.01 | −$1.14 | — | $1.01 |
| 2024 | — | −$1.30 | $0.01 | −$1.28 | — | $0.66 |
| 2025 | $0.04 | −$1.17 | $0.09 | −$1.36 | — | $0.57 |